WEDNESDAY, Sept. 1 (HealthDay News) -- Overactive blood
platelets could trigger inflammation in those with lupus, but the
anti-clotting drug Plavix might ease the painful symptoms of this
autoimmune disease, a new study suggests.
Platelets, which are the colorless, disc-shaped blood cells that
are key to clotting, are suspected to be involved in lupus,
explained senior study author Dr. Patrick Blanco, of the University
of Bordeaux in France, but "their precise role was poorly
understood until now."
Systemic lupus erythematosus (SLE) is a chronic disease thought
to develop when the body's own antibodies start attacking organs.
Sufferers experience recurring pain and inflammation in many parts
of their body. Some common symptoms include joint pain or swelling,
muscle pain, fever with no known cause, and red rashes, often on
the face, according to the U.S. National Library of Medicine.
The exact cause of lupus is unknown, although research suggests
that both environmental and genetic factors contribute to the
Presently, there is no cure for the disease, which can be fatal.
Current treatments include steroids and chemotherapy-like drugs,
but they have assorted toxic effects, the study authors noted.
Blanco and his colleagues theorized that blood platelets might
be involved in lupus because of their known role in the
inflammatory process. To test this theory, they examined the blood
of 37 lupus patients and compared their platelets to those from
individuals without the disease.
They found that platelets in people with lupus were abnormally
"activated" -- they expressed too much of a protein that's involved
in blood clotting. These activated platelets, in turn, triggered
production of proteins called interferons, which are known to
The authors found that destroying blood platelets in mice prone
to lupus relieved symptoms of the disease. They also treated these
mice with the antiplatelet drug clopidogrel (Plavix), which is
commonly used in humans to treat heart disease and stroke. The mice
showed reduced lupus symptoms and they lived three months longer
than mice that weren't treated with the drug.
The results suggest that it's possible that such anti-clotting
drugs could improve outcomes in patients with lupus, said Blanco.
He and his colleagues are currently designing clinical trials in
humans to test this possibility.
"While this is interesting, I think it's kind of early to get excited and say that this is a treatment or a cure. I would like to try this in a clinical trial," said Dr. Anca Askanase, an assistant professor of rheumatology at NYU Langone Medical Centers Hospital for Joint Diseases.
The mouse model the researchers used suggests that an
antiplatelet drug "might have a benefit in human disease as well,"
Askanase said, although "the efficacy of the mouse model is not
shutting down the disease; it's improving the disease by a little
bit. They don't get cured."
"Always when you move things from an experimental model to humans, things could be different," she added. "But Plavix is easy to test out in people, because it doesn't do anything bad to humans."
The study finding was published in the Sept. 1 issue of
Science Translational Medicine.
There's more on lupus at the
Lupus Foundation of
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.